Brought to you by 
MedImmune and Advaxis study immuno-oncology combination treatment; MedImmune could get future rights
02 Feb 2023
Executive Summary
AstraZeneca PLC’s MedImmune LLC and cancer immunotherapies company Advaxis Inc. will work together to research a new combination therapy consisting of MedImmune’s MEDI4736 and Advaxis’ ADXSHPV aimed at preventing and treating HPV-associated cervical cancer and squamous cell carcinoma of the head and neck.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune and Advaxis study immuno-oncology combination treatment; MedImmune could get future rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice